Advertisement

Journal of Neuro-Oncology

, Volume 109, Issue 1, pp 143–148 | Cite as

Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series

  • Marc C. ChamberlainEmail author
Clinical Study

Abstract

Treatment of leptomeningeal metastasis (LMD) remains challenging due to advanced systemic disease at presentation and limited treatment options. All patients underwent standard pre-treatment LMD evaluation including CSF assessment (cytology or flow cytometry), brain and spine MR imaging, and radioisotope CSF flow study. DepoCyt (liposomal cytarabine) was administered intraventricularly (n = 80) or intralumbar (n = 40) at 50 mg every 2 weeks ×4 and then every 4 weeks ×6 in responding patients. Dexamethasone (4 mg orally twice per day ×5 days) was co-administered with each DepoCyt treatment. Patients were seen with each DepoCyt treatment and assessed for toxicity. 120 adult patients [median age 51 years (range 33–68)] with LMD were treated with DepoCyt. DepoCyt Common Toxicity Criteria ≥Grade 3 neurotoxicity was seen in 60 cycles (11.5 %) in 28 patients (23.3 %). Toxicity included bacterial meningitis (3.75 % of ventricular treatments: 0 % of lumbar treatments); chemical meningitis (17.5:15 %); communicating hydrocephalus (3.75:5 %); conus medullaris/cauda equina syndrome (5:5 %); decreased visual acuity (5:2.5 %); encephalopathy (5:5 %); leukoencephalopathy (7.5:2.5 %); myelopathy (2.5:2.5 %); radiculopathy (1.25:5 %); and seizures (1.25:2.5 %). Distribution of toxicity was similar regardless of route of administration (ventricular vs. lumbar). Toxicities were transient in 34 episodes (57 %) and permanent in 26 (43 %). There were no treatment-related deaths however 20 treatment-related toxicities (32.2 %) required hospitalization. In this retrospective case series, DepoCyt is generally well tolerated however a subset of patients (12.5 %) not easily identified pre-treatment, develop serious treatment-related neurological complications that may be persistent and impact quality of life.

Keywords

Liposomal cytarabine Leptomeningeal metastases Intra-CSF chemotherapy Neurotoxicity Treatment-related toxicity 

Notes

Conflict of interest

The author reports no conflict of interest.

References

  1. 1.
    Blaney SM, Balis FM, Poplack DG (1991) Current pharmacological treatment approaches to central nervous system leukemia. Drugs 41(5):702–716PubMedCrossRefGoogle Scholar
  2. 2.
    Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5(11):3394–3402PubMedGoogle Scholar
  3. 3.
    Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow release vs. a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110–3116PubMedGoogle Scholar
  4. 4.
    Shapiro WR, Schmid M, Glantz M, Miller JJ (2006) A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol 24(6 Suppl):1528 (abstract)Google Scholar
  5. 5.
    Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, Van der Sande JJ et al (2004) The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer 40:2726–2733PubMedCrossRefGoogle Scholar
  6. 6.
    Kwong YL, Yeung DY, Chan JC (2009) Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Ann Hematol 88(3):193–201PubMedCrossRefGoogle Scholar
  7. 7.
    Fleischhack G, Jaehde U, Bode U (2005) Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet 44(1):1–31PubMedCrossRefGoogle Scholar
  8. 8.
    Goekbuget N, Hartog CM, Bassan R, Derigs HG, Dombret H, Greil R, Hernandez-Rivas JM, Huguet F, Intermesoli T, Jourdan E, Junghanss C, Leimer L, Moreno MJ, Reichle A, Ribera JM, Schmid M, Serve H, Stelljes M, Stuhlmann R, Hoelzer D (2010) Liposomal ara-C is effective and tolerable in the treatment of CNS relapse of acute lymphoblastic leukemia (ALL) and aggressive lymphoma. Haematologica [Epub Ahead of Print]Google Scholar
  9. 9.
    Chamberlain MC, Kormanik P (1996) Leptomeningeal metastases due to melanoma: combined modality therapy. Int J Oncol 9(3):505–510PubMedGoogle Scholar
  10. 10.
    Chamberlain MC, Kormanik PA, Barba D (1997) Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87:694–699PubMedCrossRefGoogle Scholar
  11. 11.
    Chamberlain MC, Kormanik PA (1998) Carcinomatous meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 55:506–512PubMedCrossRefGoogle Scholar
  12. 12.
    Chamberlain MC, Kormanik PA (1997) Non-AIDS related lymphomatous meningitis: combined modality therapy. Neurology 49:1728–1731PubMedCrossRefGoogle Scholar
  13. 13.
    Chamberlain MC, Kormanik P, Glantz M (1998) Recurrent primary central nervous system lymphoma complicated by lymphomatous meningitis. Oncol Rep 5:521–523PubMedGoogle Scholar
  14. 14.
    Chamberlain MC (2003) Combined modality treatment of leptomeningeal gliomatosis. Neurosurgery 52:324–330PubMedCrossRefGoogle Scholar
  15. 15.
    Chamberlain MC, Chalmers L (2007) Acute binocular blindness. Cancer 109:1851–1854PubMedCrossRefGoogle Scholar
  16. 16.
    Chamberlain M, Glantz MJ (2008) Myelomatous meningitis: multimodal therapy. Cancer 112:1562–1567PubMedCrossRefGoogle Scholar
  17. 17.
    Chamberlain MC, Johnston S, Van Horn A, Glantz MJ (2009) Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol 91(3):271–277PubMedCrossRefGoogle Scholar
  18. 18.
    Jabbour E, O’Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA (2007) Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood [Epub Ahead of Print]Google Scholar
  19. 19.
    Hilgendorf I, Wolff D, Junghanss C, Kahl C, Leithaeuser M, Steiner B, Casper J, Freund M (2008) Neurological complications after intrathecal liposomal cytarabine application in patients after allogenic hematopoietic stem cell transplantation. Ann Hematol 87(12):1009–1012PubMedCrossRefGoogle Scholar
  20. 20.
    Gállego Pérez-Larraya J, Palma JA, Carmona-Iragui M, Fernández-Torrón R, Irimia P, Rodríguez-Otero P, Panizo C, Martínez-Vila E (2010) Neurologic complications of intrathecal liposomal cytarabine administered prophylactic ally to patients with non-Hodgkin’s lymphoma. J Neurooncol [Epub Ahead of Print]Google Scholar
  21. 21.
    Ostermann K, Pels H, Kowoll A, Kuhnhenn J, Schlegel U (2010) Neurological complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. J Neurooncol [Epub Ahead of Print]Google Scholar
  22. 22.
    Siegal T (2003) Toxicity for treatment of neoplastic meningitis. Curr Oncol Rep 5(1):41–49PubMedCrossRefGoogle Scholar
  23. 23.
    Watterson J, Toogood I, Nieder M, Morse M, Frierdich S, Lee Y, Moertel CL, Priest JR (1994) Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer 74(11):3034–3041PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  1. 1.Department of Neurology and NeurosurgeryUniversity of WashingtonSeattleUSA
  2. 2.Seattle Cancer Care Alliance, Fred Hutchinson Cancer CenterSeattleUSA

Personalised recommendations